Cargando…

Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study

BACKGROUND: Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and treatment outcomes in treatment-eligible patients with COVID-19 receiving home-based care. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jin Ju, Lee, Jacob, Seo, Yu Bin, Na, Sun Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840968/ https://www.ncbi.nlm.nih.gov/pubmed/36450290 http://dx.doi.org/10.3947/ic.2022.0123

Ejemplares similares

Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019
por: Park, Hailey J, et al.
Publicado: (2023)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
por: Tavares-Júnior, José Wagner Leonel, et al.
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
por: Kim, Haein, et al.
Publicado: (2022)

Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
por: Park, Jin Ju, et al.
Publicado: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
por: Congdon, Seth, et al.
Publicado: (2023)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
por: Blair, Hannah A.
Publicado: (2022)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2023)

Drug-induced Liver Injury With Ritonavir-Boosted Nirmatrelvir: Evidence From Coronavirus Disease 2019 Emergency Use Authorization Adverse Event Reporting System
por: Li, Guo-Fu, et al.
Publicado: (2023)

Predicting the public health impact of bivalent vaccines and nirmatrelvir-ritonavir against COVID-19
por: Park, Hailey J., et al.
Publicado: (2023)

Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients
por: Kim, Min-Kyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4co66mb3t2ngvjklc8mftcevgd